JP2015533795A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015533795A5 JP2015533795A5 JP2015531286A JP2015531286A JP2015533795A5 JP 2015533795 A5 JP2015533795 A5 JP 2015533795A5 JP 2015531286 A JP2015531286 A JP 2015531286A JP 2015531286 A JP2015531286 A JP 2015531286A JP 2015533795 A5 JP2015533795 A5 JP 2015533795A5
- Authority
- JP
- Japan
- Prior art keywords
- hvr
- seq
- amino acid
- acid sequence
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 55
- 239000000427 antigen Substances 0.000 claims 25
- 102000036639 antigens Human genes 0.000 claims 25
- 108091007433 antigens Proteins 0.000 claims 25
- 239000012634 fragment Substances 0.000 claims 25
- 101000623903 Homo sapiens Cell surface glycoprotein MUC18 Proteins 0.000 claims 6
- 102100023126 Cell surface glycoprotein MUC18 Human genes 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- PJOHVEQSYPOERL-SHEAVXILSA-N (e)-n-[(4r,4as,7ar,12br)-3-(cyclopropylmethyl)-9-hydroxy-7-oxo-2,4,5,6,7a,13-hexahydro-1h-4,12-methanobenzofuro[3,2-e]isoquinoline-4a-yl]-3-(4-methylphenyl)prop-2-enamide Chemical compound C1=CC(C)=CC=C1\C=C\C(=O)N[C@]1(CCC(=O)[C@@H]2O3)[C@H]4CC5=CC=C(O)C3=C5[C@]12CCN4CC1CC1 PJOHVEQSYPOERL-SHEAVXILSA-N 0.000 claims 3
- 210000003169 central nervous system Anatomy 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 2
- 102000051110 human MCAM Human genes 0.000 claims 2
- 230000008595 infiltration Effects 0.000 claims 2
- 238000001764 infiltration Methods 0.000 claims 2
- 208000027866 inflammatory disease Diseases 0.000 claims 2
- 241000894006 Bacteria Species 0.000 claims 1
- 206010012442 Dermatitis contact Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 208000002029 allergic contact dermatitis Diseases 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261698916P | 2012-09-10 | 2012-09-10 | |
| US61/698,916 | 2012-09-10 | ||
| US201261797179P | 2012-11-30 | 2012-11-30 | |
| US61/797,179 | 2012-11-30 | ||
| US201261797356P | 2012-12-05 | 2012-12-05 | |
| US61/797,356 | 2012-12-05 | ||
| PCT/US2013/058773 WO2014039975A2 (en) | 2012-09-10 | 2013-09-09 | Anti-mcam antibodies and associated methods of use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015533795A JP2015533795A (ja) | 2015-11-26 |
| JP2015533795A5 true JP2015533795A5 (OSRAM) | 2016-11-04 |
| JP6339574B2 JP6339574B2 (ja) | 2018-06-06 |
Family
ID=50237783
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015531286A Expired - Fee Related JP6339574B2 (ja) | 2012-09-10 | 2013-09-09 | 抗ｍｃａｍ抗体及び関連する使用方法 |
Country Status (23)
| Country | Link |
|---|---|
| US (6) | US20150239980A1 (OSRAM) |
| EP (2) | EP3530287A1 (OSRAM) |
| JP (1) | JP6339574B2 (OSRAM) |
| KR (1) | KR102194568B1 (OSRAM) |
| CN (2) | CN107266571A (OSRAM) |
| AR (1) | AR092488A1 (OSRAM) |
| AU (2) | AU2013312203B2 (OSRAM) |
| CA (1) | CA2884463A1 (OSRAM) |
| CL (1) | CL2015000582A1 (OSRAM) |
| CO (1) | CO7400878A2 (OSRAM) |
| CU (1) | CU20150023A7 (OSRAM) |
| DK (1) | DK2892562T3 (OSRAM) |
| EA (1) | EA201590528A1 (OSRAM) |
| ES (1) | ES2718208T3 (OSRAM) |
| IL (1) | IL237625A0 (OSRAM) |
| MX (1) | MX2015002918A (OSRAM) |
| MY (1) | MY182427A (OSRAM) |
| PE (1) | PE20151286A1 (OSRAM) |
| PH (1) | PH12015500514A1 (OSRAM) |
| SG (2) | SG11201501773RA (OSRAM) |
| TW (3) | TWI660972B (OSRAM) |
| WO (1) | WO2014039975A2 (OSRAM) |
| ZA (1) | ZA201501858B (OSRAM) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2006381T3 (en) | 2006-03-31 | 2016-02-22 | Chugai Pharmaceutical Co Ltd | PROCEDURE FOR REGULATING ANTIBODIES BLOOD PHARMACOKINETICS |
| DK2202245T3 (en) | 2007-09-26 | 2016-11-21 | Chugai Pharmaceutical Co Ltd | A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR |
| PT2708559T (pt) | 2008-04-11 | 2018-05-16 | Chugai Pharmaceutical Co Ltd | Molécula de ligação ao antigénio capaz de se ligar repetidamente a duas ou mais moléculas de antigénio |
| MX365235B (es) | 2010-11-30 | 2019-05-28 | Chugai Pharmaceutical Co Ltd | Molécula de unión a antígeno capaz de unir repetidamente a la pluralidad de moléculas de antígeno. |
| WO2014030750A1 (ja) | 2012-08-24 | 2014-02-27 | 中外製薬株式会社 | マウスFcγRII特異的Fc抗体 |
| TWI855488B (zh) | 2012-08-24 | 2024-09-11 | 日商中外製藥股份有限公司 | FcγRIIb特異性Fc區域變異體 |
| TWI660972B (zh) | 2012-09-10 | 2019-06-01 | 愛爾蘭商尼歐托普生物科學公司 | 抗ｍｃａｍ抗體及相關使用方法 |
| SG11201508170TA (en) | 2013-04-02 | 2015-11-27 | Chugai Pharmaceutical Co Ltd | Fc REGION VARIANT |
| CA2938933A1 (en) | 2014-03-12 | 2015-09-17 | Prothena Biosciences Limited | Anti-laminin4 antibodies specific for lg4-5 |
| ES2744526T3 (es) * | 2014-03-12 | 2020-02-25 | Prothena Biosciences Ltd | Anticuerpos anti-MCAM y métodos de uso asociados |
| TW201623331A (zh) * | 2014-03-12 | 2016-07-01 | 普羅帝納生物科學公司 | 抗黑色素瘤細胞黏著分子（ｍｃａｍ）抗體類及使用彼等之相關方法 |
| KR20170052526A (ko) * | 2014-03-13 | 2017-05-12 | 프로테나 바이오사이언시즈 리미티드 | 다발성 경화증에 대한 병용 치료 |
| WO2016022694A1 (en) * | 2014-08-05 | 2016-02-11 | The University Of Chicago | Modulation of laminin alpha-4 in the prevention, treatment, and management of metabolic syndromes |
| MX2017005774A (es) | 2014-12-19 | 2017-07-28 | Chugai Pharmaceutical Co Ltd | Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso. |
| SG11201706014PA (en) | 2015-02-05 | 2017-08-30 | Chugai Pharmaceutical Co Ltd | Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof |
| CN104710513A (zh) * | 2015-04-06 | 2015-06-17 | 苏州普罗达生物科技有限公司 | 黑色素瘤细胞粘附分子拮抗剂多肽及其应用 |
| CN104725483A (zh) * | 2015-04-06 | 2015-06-24 | 苏州普罗达生物科技有限公司 | 一种黑色素瘤细胞粘附分子拮抗剂多肽及其应用 |
| WO2017046776A2 (en) * | 2015-09-16 | 2017-03-23 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis |
| WO2017046774A2 (en) * | 2015-09-16 | 2017-03-23 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis |
| MX2018006973A (es) | 2015-12-09 | 2019-05-16 | Corvus Pharmaceuticals Inc | Anticuerpos anti-cd73 humanizados. |
| JP7141336B2 (ja) | 2015-12-25 | 2022-09-22 | 中外製薬株式会社 | 抗ミオスタチン抗体および使用方法 |
| WO2017149513A1 (en) | 2016-03-03 | 2017-09-08 | Prothena Biosciences Limited | Anti-mcam antibodies and associated methods of use |
| WO2017153953A1 (en) * | 2016-03-09 | 2017-09-14 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of granulomatous lung diseases |
| WO2017208210A1 (en) | 2016-06-03 | 2017-12-07 | Prothena Biosciences Limited | Anti-mcam antibodies and associated methods of use |
| KR102538749B1 (ko) | 2016-08-05 | 2023-06-01 | 추가이 세이야쿠 가부시키가이샤 | Il-8 관련 질환의 치료용 또는 예방용 조성물 |
| WO2018223140A1 (en) * | 2017-06-02 | 2018-12-06 | Prothena Biosciences Limited | Anti-mcam antibodies and associated methods of use |
| CA3087058A1 (en) * | 2017-12-26 | 2019-07-04 | The Regents Of The University Of California | Human antibodies that bind and are internalized by mesothelioma and other cancer cells |
| AU2019401657B2 (en) * | 2018-12-21 | 2025-10-09 | Multitude Therapeutics Inc. | Antibodies specific to MUC18 |
| JP7575102B2 (ja) | 2018-12-21 | 2024-10-29 | マルチチュード インコーポレーテッド | Ｍｕｃ１８に特異的な抗体 |
| EP4263600A1 (en) | 2020-12-18 | 2023-10-25 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| EP4463135A2 (en) | 2022-01-10 | 2024-11-20 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| EP4572772A1 (en) | 2022-08-17 | 2025-06-25 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| EP4602174A1 (en) | 2022-10-13 | 2025-08-20 | Sana Biotechnology, Inc. | Viral particles targeting hematopoietic stem cells |
| EP4627096A1 (en) | 2022-12-02 | 2025-10-08 | Sana Biotechnology, Inc. | Lipid particles with cofusogens and methods of producing and using the same |
| AU2024274792A1 (en) | 2023-05-23 | 2025-10-23 | Sana Biotechnology, Inc. | Tandem fusogens and related lipid particles |
| US12311033B2 (en) | 2023-05-31 | 2025-05-27 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025184529A1 (en) | 2024-03-01 | 2025-09-04 | Sana Biotechnology, Inc. | Viral particles with fusogen display and related compositions and methods |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| GB1520819A (en) | 1976-05-10 | 1978-08-09 | Robertson H J | Medical protein hydrolysate process of making the same and processes of utilizing the protein hydrolysate to aid in healing traumatized areas |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5206161A (en) | 1991-02-01 | 1993-04-27 | Genentech, Inc. | Human plasma carboxypeptidase B |
| US7192584B2 (en) * | 1991-03-18 | 2007-03-20 | Centocor, Inc. | Methods of treating psoriasis with anti-TNF antibodies |
| US6225447B1 (en) | 1991-05-15 | 2001-05-01 | Cambridge Antibody Technology Ltd. | Methods for producing members of specific binding pairs |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US5224539A (en) | 1991-06-14 | 1993-07-06 | Coen Company, Inc. | Cooling system for air heaters and the like |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| US5840299A (en) | 1994-01-25 | 1998-11-24 | Athena Neurosciences, Inc. | Humanized antibodies against leukocyte adhesion molecule VLA-4 |
| US7435802B2 (en) | 1994-01-25 | 2008-10-14 | Elan Pharaceuticals, Inc. | Humanized anti-VLA4 immunoglobulins |
| GB9406974D0 (en) | 1994-04-08 | 1994-06-01 | Pharmaceutical Proteins Ltd | Transgenic production |
| JP4312259B2 (ja) | 1995-04-27 | 2009-08-12 | アムジェン フレモント インク． | 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体 |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| US6113898A (en) | 1995-06-07 | 2000-09-05 | Idec Pharmaceuticals Corporation | Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies |
| DE19544393A1 (de) | 1995-11-15 | 1997-05-22 | Hoechst Schering Agrevo Gmbh | Synergistische herbizide Mischungen |
| DE69738539T2 (de) | 1996-12-03 | 2009-03-26 | Amgen Fremont Inc. | Vollkommen humane Antikörper die EGFR binden |
| AU757961B2 (en) | 1998-09-30 | 2003-03-13 | Sankyo Company Limited | Anti-Fas antibodies |
| US20040220103A1 (en) | 1999-04-19 | 2004-11-04 | Immunex Corporation | Soluble tumor necrosis factor receptor treatment of medical disorders |
| US7192931B2 (en) | 2000-10-12 | 2007-03-20 | Neuren Pharmaceuticals Ltd. | Treatment of demyelinating diseases |
| US6866866B1 (en) | 2000-11-03 | 2005-03-15 | Andrx Labs, Llc | Controlled release metformin compositions |
| AU2002252444A1 (en) | 2001-03-23 | 2002-10-08 | Board Of Regents, The University Of Texas System | Methods for inhibition of angiogenesis, tumor growth and metastasis by fully human anti-il8 and anti-muc18 in diverse types of tumors |
| WO2003005783A2 (en) | 2001-07-03 | 2003-01-16 | Sciperio, Inc. | Methods and systems for embedding electrical components in a device including a frequency responsive structure |
| TWI334439B (en) | 2001-08-01 | 2010-12-11 | Centocor Inc | Anti-tnf antibodies, compositions, methods and uses |
| JP2005516965A (ja) * | 2001-12-28 | 2005-06-09 | アブジェニックス・インコーポレーテッド | 抗ｍｕｃ１８抗体を使用する方法 |
| EP1470146B8 (en) | 2001-12-28 | 2007-09-12 | Amgen Fremont Inc. | Antibodies against the muc18 antigen |
| JP2005514409A (ja) | 2001-12-28 | 2005-05-19 | アブジェニックス・インコーポレーテッド | Ｍｕｃ１８抗原に対する抗体の使用 |
| CA2488441C (en) | 2002-06-03 | 2015-01-27 | Genentech, Inc. | Synthetic antibody phage libraries |
| WO2003105782A2 (en) | 2002-06-17 | 2003-12-24 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Specificity grafting of a murine antibody onto a human framework |
| US20060275287A1 (en) * | 2002-06-21 | 2006-12-07 | Brad St Croix | Scroll compressor |
| EP1382615A1 (en) * | 2002-07-15 | 2004-01-21 | Xerion Pharmaceuticals AG | MCAM inhibitors |
| KR20050114212A (ko) | 2003-01-24 | 2005-12-05 | 엘란 파마슈티칼스, 인크. | 수초재생제의 투여에 의한 탈수초성 질환 및 마비의 치료및 조성물 |
| UY28886A1 (es) * | 2004-05-10 | 2005-12-30 | Boehringer Ingelheim Int | Anticuerpos que consisten en polipéptidos y derivados conprendiendo tres secuencias conteniendo respectivamente los siguientes números de seq. id: 1-3 y 4-6; 7-9 y 10-12 y 13-15 ó 16-18 |
| EA014226B1 (ru) * | 2004-07-26 | 2010-10-29 | Байоджен Айдек Ма Инк. | Антитела к cd154, их фрагменты и способы применения антител и фрагментов |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| WO2007058725A2 (en) | 2005-10-12 | 2007-05-24 | The Regents Of The University Of California | Engineered antibody fragment that irreversibly binds an antigen |
| EP1963370A1 (en) * | 2005-12-06 | 2008-09-03 | Domantis Limited | Bispecific ligands with binding specificity to cell surface targets and methods of use therefor |
| WO2009028663A1 (ja) | 2007-08-30 | 2009-03-05 | Kyowa Hakko Kirin Co., Ltd. | 抗Claudin-3抗体 |
| US20120047586A9 (en) | 2007-10-24 | 2012-02-23 | Otsuka Chemical Co., Ltd | Polypeptide having enhanced effector function |
| CA2705292C (en) * | 2007-11-13 | 2016-06-21 | Teva Biopharmaceuticals Usa, Inc. | Humanized antibodies against tl1a |
| NZ585516A (en) | 2007-12-21 | 2012-07-27 | Hoffmann La Roche | Anti-cd20 antibody formulation |
| US8155019B2 (en) * | 2008-01-07 | 2012-04-10 | Canon Kabushiki Kaisha | Information processing apparatus, device information display method, and computer-readable storage medium |
| AR070141A1 (es) | 2008-01-23 | 2010-03-17 | Glenmark Pharmaceuticals Sa | Anticuerpos humanizados especificos para el factor von willebrand |
| US8293468B2 (en) | 2009-06-10 | 2012-10-23 | Centre Hospitalier De L'université De Montréal | MCAM modulation and uses thereof |
| WO2011013753A1 (ja) * | 2009-07-29 | 2011-02-03 | シスメックス株式会社 | ヒトil-17産生ヘルパーt細胞検出用マーカーおよび試薬、並びにヒトil-17産生ヘルパーt細胞の検出方法 |
| WO2011100477A2 (en) * | 2010-02-10 | 2011-08-18 | Taiga Biotechnologies, Inc. | Antibodies and processes for preparing the same |
| SG10201501562VA (en) | 2010-03-02 | 2015-04-29 | Abbvie Inc | Therapeutic dll4 binding proteins |
| EP2601532B1 (en) | 2010-08-06 | 2016-01-27 | Mycartis N.V. | Perlecan as a biomarker for renal dysfunction |
| US9062101B2 (en) | 2010-08-14 | 2015-06-23 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
| ES2859639T3 (es) | 2010-11-25 | 2021-10-04 | Allecra Therapeutics Gmbh | Compuestos y su uso |
| JP5946605B2 (ja) * | 2011-01-28 | 2016-07-06 | シスメックス株式会社 | ヒトｉｌ−１７産生ヘルパーｔ細胞の検出方法 |
| EP2718327A1 (en) * | 2011-06-06 | 2014-04-16 | Neotope Biosciences Limited | Mcam antagonists and methods of treatment |
| NZ629204A (en) | 2012-02-16 | 2016-09-30 | Santarus Inc | Anti-vla1 (cd49a) antibody pharmaceutical compositions |
| US20140004131A1 (en) | 2012-05-04 | 2014-01-02 | Novartis Ag | Antibody formulation |
| US9216219B2 (en) | 2012-06-12 | 2015-12-22 | Novartis Ag | Anti-BAFFR antibody formulation |
| TWI660972B (zh) | 2012-09-10 | 2019-06-01 | 愛爾蘭商尼歐托普生物科學公司 | 抗ｍｃａｍ抗體及相關使用方法 |
| EP3892288A1 (en) | 2013-10-24 | 2021-10-13 | Astrazeneca AB | Stable, aqueous antibody formulations |
| WO2015136570A1 (ja) | 2014-03-11 | 2015-09-17 | パナソニック液晶ディスプレイ株式会社 | 表示装置及びその駆動方法 |
| US20170129954A1 (en) | 2014-03-12 | 2017-05-11 | Prothena Biosciences Limited | Use of Anti-MCAM Antibodies for Treatment or Prophylaxis of Giant Cell Arteritis, Polymyalgia Rheumatica or Takayasus Arteritis |
| KR20160131082A (ko) | 2014-03-12 | 2016-11-15 | 프로테나 바이오사이언시즈 리미티드 | Lg1-3에 특이적인 항-라미닌4 항체 |
| US20170101470A1 (en) | 2014-03-12 | 2017-04-13 | Prothena Biosciences Limited | Use of Anti-MCAM Antibodies for Treatment or Prophylaxis of Giant Cell Arteritis, Polymyalgia Rheumatica or Takayasus Arteritis |
| ES2744526T3 (es) | 2014-03-12 | 2020-02-25 | Prothena Biosciences Ltd | Anticuerpos anti-MCAM y métodos de uso asociados |
| TW201623331A (zh) | 2014-03-12 | 2016-07-01 | 普羅帝納生物科學公司 | 抗黑色素瘤細胞黏著分子（ｍｃａｍ）抗體類及使用彼等之相關方法 |
| CA2938933A1 (en) | 2014-03-12 | 2015-09-17 | Prothena Biosciences Limited | Anti-laminin4 antibodies specific for lg4-5 |
| KR20170052526A (ko) | 2014-03-13 | 2017-05-12 | 프로테나 바이오사이언시즈 리미티드 | 다발성 경화증에 대한 병용 치료 |
| WO2017046774A2 (en) | 2015-09-16 | 2017-03-23 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis |
| WO2017046776A2 (en) | 2015-09-16 | 2017-03-23 | Prothena Biosciences Limited | Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis |
| WO2017149513A1 (en) | 2016-03-03 | 2017-09-08 | Prothena Biosciences Limited | Anti-mcam antibodies and associated methods of use |
| WO2017208210A1 (en) | 2016-06-03 | 2017-12-07 | Prothena Biosciences Limited | Anti-mcam antibodies and associated methods of use |
| WO2018223140A1 (en) | 2017-06-02 | 2018-12-06 | Prothena Biosciences Limited | Anti-mcam antibodies and associated methods of use |
-
2013
- 2013-09-06 TW TW106116728A patent/TWI660972B/zh not_active IP Right Cessation
- 2013-09-06 TW TW102132203A patent/TWI595007B/zh not_active IP Right Cessation
- 2013-09-06 TW TW108108483A patent/TW201922795A/zh unknown
- 2013-09-09 AU AU2013312203A patent/AU2013312203B2/en not_active Ceased
- 2013-09-09 CN CN201710411450.3A patent/CN107266571A/zh active Pending
- 2013-09-09 US US14/427,290 patent/US20150239980A1/en not_active Abandoned
- 2013-09-09 DK DK13836030.0T patent/DK2892562T3/en active
- 2013-09-09 EA EA201590528A patent/EA201590528A1/ru unknown
- 2013-09-09 EP EP19155167.0A patent/EP3530287A1/en not_active Withdrawn
- 2013-09-09 KR KR1020157008706A patent/KR102194568B1/ko not_active Expired - Fee Related
- 2013-09-09 ES ES13836030T patent/ES2718208T3/es active Active
- 2013-09-09 PE PE2015000328A patent/PE20151286A1/es not_active Application Discontinuation
- 2013-09-09 WO PCT/US2013/058773 patent/WO2014039975A2/en not_active Ceased
- 2013-09-09 US US14/021,777 patent/US9447190B2/en not_active Expired - Fee Related
- 2013-09-09 SG SG11201501773RA patent/SG11201501773RA/en unknown
- 2013-09-09 JP JP2015531286A patent/JP6339574B2/ja not_active Expired - Fee Related
- 2013-09-09 EP EP13836030.0A patent/EP2892562B1/en active Active
- 2013-09-09 AR ARP130103202A patent/AR092488A1/es unknown
- 2013-09-09 CN CN201380047188.9A patent/CN105120895A/zh active Pending
- 2013-09-09 CA CA2884463A patent/CA2884463A1/en not_active Abandoned
- 2013-09-09 SG SG10201708127UA patent/SG10201708127UA/en unknown
- 2013-09-09 MY MYPI2015700717A patent/MY182427A/en unknown
- 2013-09-09 MX MX2015002918A patent/MX2015002918A/es unknown
-
2015
- 2015-03-09 CL CL2015000582A patent/CL2015000582A1/es unknown
- 2015-03-09 IL IL237625A patent/IL237625A0/en unknown
- 2015-03-10 PH PH12015500514A patent/PH12015500514A1/en unknown
- 2015-03-10 CU CUP2015000023A patent/CU20150023A7/es unknown
- 2015-03-18 ZA ZA2015/01858A patent/ZA201501858B/en unknown
- 2015-04-08 CO CO15077895A patent/CO7400878A2/es unknown
-
2016
- 2016-07-28 US US15/222,849 patent/US10414825B2/en not_active Expired - Fee Related
- 2016-07-28 US US15/222,848 patent/US10407507B2/en not_active Expired - Fee Related
-
2017
- 2017-10-05 US US15/726,170 patent/US10584177B2/en not_active Expired - Fee Related
-
2018
- 2018-10-04 AU AU2018241135A patent/AU2018241135B2/en not_active Ceased
-
2020
- 2020-01-16 US US16/745,178 patent/US20200216560A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015533795A5 (OSRAM) | ||
| HRP20200767T1 (hr) | Humanizirana anti-humana cd19 protutijela i postupci uporabe | |
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| JP2017518258A5 (OSRAM) | ||
| JP2017536102A5 (OSRAM) | ||
| FI3487882T3 (fi) | Gprc5d-vasta-aineita, bispesifisiä antigeeniä sitovia molekyylejä, jotka sitovat gprc5d:tä ja cd3:a, sekä niiden käyttötapoja | |
| PE20201186A1 (es) | Anticuerpos antitau y metodos de uso | |
| JP2015510510A5 (OSRAM) | ||
| HRP20221141T1 (hr) | Anti-lag3 protutijela | |
| RU2013143358A (ru) | Анти-fgfr4 антитела и способы их применения | |
| JP2016512551A5 (OSRAM) | ||
| JP2020500538A5 (OSRAM) | ||
| SI3013861T1 (en) | Anti-FcRH5 antibodies | |
| HRP20201493T1 (hr) | Anti-alfa-sinukleinska protutijela i postupci uporabe | |
| JP2012116856A5 (OSRAM) | ||
| NZ602040A (en) | Anti-lrp6 antibodies | |
| RU2017119543A (ru) | Анти-tim3 антитела и способы их применения | |
| JP2014511179A5 (OSRAM) | ||
| WO2015032906A4 (en) | Cd70-binding peptides and method, process and use relating thereto | |
| JP2011509245A5 (OSRAM) | ||
| JP2014158469A5 (OSRAM) | ||
| RU2017125758A (ru) | Антитела к с5 и способы их применения | |
| NZ602892A (en) | Antibodies that bind human cd27 and uses thereof | |
| NZ758448A (en) | Anti-sortilin antibodies and methods of use thereof | |
| JP2013198490A5 (OSRAM) |